Clinical Trials Browser

Phase 2 × Active not recruiting × Paraproteinemias × Clear all

NCT03236428 2025-03-05

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Phase 2 Active not recruiting

Smoldering Multiple Myeloma, Paraproteinemias